Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020

This statistic shows the percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017 to 2020. Nearly nine percent of executives stated they think drug spending reduction due to biosimilars will come into effect in 2017, while 25 percent think it will happen in 2020.

本统计数据显示了2017年至2020年间，美国医疗保健行业高级管理人员中预计生物类似物将降低专科药物支出比例的百分比。其中，近九百分之一的执行人员认为，由于生物类似物的应用，药物支出降低将在2017年开始显现，而25%的执行人员则认为这一影响将在2020年显现。